12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HX575: Phase III started

Novartis said its Sandoz unit began a U.S. Phase III trial of a biosimilar version of anemia drug epoetin alfa that is intended to support FDA approval of the erythropoietin (EPO). The double-blind trial of the biosimilar - HX575 -...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >